Chemotherapeutic options for the treatment of human trichomoniasis

Trichomonas vaginalis is the causative agent of human trichomoniasis, with an estimated worldwide prevalence of 170 million cases per year. This rate has significantly increased in the past 10 years [1]. Overall, trichomoniasis was estimated to have caused 198,000 years of life with disability in 2016 [1]. Reported percentages of asymptomatic cases vary from 11-85 % in women [2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14] and 56.25-76.8 % in men [3, 15], and the estimated number of unreported cases of individuals exposed to infection can be assumed to be much higher.
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Tags: Review Source Type: research